CreativeOne Wealth LLC Has $527,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

CreativeOne Wealth LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 147.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,185 shares of the medical instruments supplier’s stock after buying an additional 1,302 shares during the period. CreativeOne Wealth LLC’s holdings in Becton, Dickinson and Company were worth $527,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Livelsberger Financial Advisory acquired a new position in Becton, Dickinson and Company in the 3rd quarter worth about $26,000. Ashton Thomas Securities LLC acquired a new position in shares of Becton, Dickinson and Company in the third quarter valued at approximately $33,000. Tompkins Financial Corp raised its holdings in Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 46 shares during the last quarter. Sound Income Strategies LLC boosted its position in Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the period. Finally, Kennebec Savings Bank bought a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $46,000. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $221.90 on Monday. The business has a 50-day moving average price of $234.16 and a two-hundred day moving average price of $234.10. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $249.89. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The company has a market cap of $64.14 billion, a P/E ratio of 37.36, a PEG ratio of 1.65 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter last year, the firm posted $3.42 earnings per share. The firm’s revenue was up 6.9% on a year-over-year basis. As a group, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.87%. The ex-dividend date of this dividend is Monday, December 9th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s payout ratio is presently 63.97%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on BDX shares. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI raised their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.